Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry
Authors' conclusion
TOF effectiveness (CDAI LDA) was observed in a US real-world setting of patients with RA regardless of TOF regimen, line of therapy, time of initiation, and dose.
Study context
- Population
- Patients with rheumatoid arthritis (RA) initiating tofacitinib in the US CorEvitas RA Registry, November 2012 to January 20211,298 with 12-month follow-up
- Participants
- 2,874 patients
- Outcome
- CDAI low disease activity (CDAI LDA)
- Follow-up
- 12 months
Methodological detailsreal-world, descriptive analysis, stratified by tofacitinib (TOF) regimen, line of therapy, time of initiation and dose
- Real-world
- Descriptive analysis
- Stratified by TOF regimen, line of therapy, time of initiation and dose
Main finding
As reported in the abstract
CDAI LDA
TOF
31.9%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| CDAI remission · 12 months | TOF 10.1% |
| ≥ 20%, ≥ 50% and ≥ 70% improvement in modified ACR core set measures · 12 months | TOF ≥ 20% improvement 22.4% · ≥ 50% improvement 10.4% · ≥ 70% improvement 5% |
| Treatment patterns | TOF Monotherapy 43.1% · Fourth-line therapy 66.5% · TNFi immediately prior 40.8% · Initiation for lack/loss of efficacy of prior treatment 67.7% |
PROs · 12 months
- Improvements in PROs were observed
Original publication
Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry. J Rheumatol. Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →